FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016810014> ?p ?o ?g. }

• W3016810014 endingPage "1480" @default.
• W3016810014 startingPage "1467" @default.
• W3016810014 abstract "IntroductionThe safety and efficacy of exenatide once weekly (EQW) is overall well established. EQW is primarily renally eliminated. In this study, the efficacy and renal and gastrointestinal tolerability of EQW were summarised in participants with type 2 diabetes and chronic kidney disease stage 3 (CKD3; moderate renal impairment; estimated glomerular filtration rate [eGFR] ≥ 30 to < 60 mL/min/1.73 m2) or CKD stage 2 (CKD2; mild renal impairment; eGFR ≥ 60 to < 90 mL/min/1.73 m2).MethodsData on participants with type 2 diabetes and baseline CKD3 or CKD2 from eight phase 3, double-blind or open-label studies with 26- or 28-week controlled treatment periods were pooled. Participants received EQW or a placebo/non-glucagon-like peptide-1 receptor agonist comparator (sitagliptin, metformin, pioglitazone, dapagliflozin and insulin).ResultsParticipants with baseline CKD3 (N = 182) or CKD2 (N = 772) receiving EQW differed in a number of baseline characteristics, such as age < 65 years, race, mean body mass index and mean type 2 diabetes duration, whereas mean blood pressure and glycated haemoglobin (HbA1c) were similar. Mean reductions in HbA1c, body weight and systolic blood pressure from baseline to week 26/28 in participants receiving EQW were similar between the CKD subgroups. The proportions of participants (CKD3 and CKD2) with any adverse event (AE) were 81% and 72%, respectively, for EQW and 74% and 68%, respectively, for all comparators; those for serious AEs were 2.7% and 3.4%, respectively, for EQW and 6% and 5%, respectively, for all comparators. Gastrointestinal AE rates were higher in the EQW CKD3 subgroup (42.2% of participants) than in the CKD2 (32.8%) subgroup, although rates for nausea and vomiting were similar. There were no dehydration events; one participant in each treatment group had a serious AE of acute kidney injury (EQW with CKD3, n = 1; pioglitazone with CKD2, n = 1).ConclusionExenatide once weekly was well tolerated and demonstrated similar efficacy in participants with type 2 diabetes with mild and moderate renal impairment.Trial RegistrationClinicalTrials.gov identifiers: NCT00637273, NCT00676338, NCT02229383, NCT02229396, NCT00641056, NCT01652729, NCT00935532, NCT01003184." @default.
• W3016810014 created "2020-04-24" @default.
• W3016810014 creator A5002278673 @default.
• W3016810014 creator A5035768013 @default.
• W3016810014 creator A5041913215 @default.
• W3016810014 creator A5050249929 @default.
• W3016810014 creator A5060489809 @default.
• W3016810014 creator A5076877188 @default.
• W3016810014 creator A5086072427 @default.
• W3016810014 date "2020-04-18" @default.
• W3016810014 modified "2023-10-18" @default.
• W3016810014 title "Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease" @default.
• W3016810014 cites W1944521216 @default.
• W3016810014 cites W1989713397 @default.
• W3016810014 cites W2001097346 @default.
• W3016810014 cites W2013137401 @default.
• W3016810014 cites W2072691447 @default.
• W3016810014 cites W2073742622 @default.
• W3016810014 cites W2099352903 @default.
• W3016810014 cites W2107949845 @default.
• W3016810014 cites W2136546775 @default.
• W3016810014 cites W2150189780 @default.
• W3016810014 cites W2152189242 @default.
• W3016810014 cites W2236659707 @default.
• W3016810014 cites W2464122426 @default.
• W3016810014 cites W2470687038 @default.
• W3016810014 cites W2519803668 @default.
• W3016810014 cites W2553778225 @default.
• W3016810014 cites W2588441560 @default.
• W3016810014 cites W2668743363 @default.
• W3016810014 cites W2727832032 @default.
• W3016810014 cites W2754041380 @default.
• W3016810014 cites W275794622 @default.
• W3016810014 cites W2790570046 @default.
• W3016810014 cites W2791169690 @default.
• W3016810014 cites W2808008353 @default.
• W3016810014 cites W2809136812 @default.
• W3016810014 cites W2913046323 @default.
• W3016810014 cites W2948370538 @default.
• W3016810014 doi "https://doi.org/10.1007/s13300-020-00815-z" @default.
• W3016810014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7324446" @default.
• W3016810014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32306296" @default.
• W3016810014 hasPublicationYear "2020" @default.
• W3016810014 type Work @default.
• W3016810014 sameAs 3016810014 @default.
• W3016810014 citedByCount "4" @default.
• W3016810014 countsByYear W30168100142022 @default.
• W3016810014 countsByYear W30168100142023 @default.
• W3016810014 crossrefType "journal-article" @default.
• W3016810014 hasAuthorship W3016810014A5002278673 @default.
• W3016810014 hasAuthorship W3016810014A5035768013 @default.
• W3016810014 hasAuthorship W3016810014A5041913215 @default.
• W3016810014 hasAuthorship W3016810014A5050249929 @default.
• W3016810014 hasAuthorship W3016810014A5060489809 @default.
• W3016810014 hasAuthorship W3016810014A5076877188 @default.
• W3016810014 hasAuthorship W3016810014A5086072427 @default.
• W3016810014 hasBestOaLocation W30168100141 @default.
• W3016810014 hasConcept C126322002 @default.
• W3016810014 hasConcept C134018914 @default.
• W3016810014 hasConcept C159641895 @default.
• W3016810014 hasConcept C2777180221 @default.
• W3016810014 hasConcept C2778384471 @default.
• W3016810014 hasConcept C2779284873 @default.
• W3016810014 hasConcept C2779306644 @default.
• W3016810014 hasConcept C2780323712 @default.
• W3016810014 hasConcept C2780533449 @default.
• W3016810014 hasConcept C555293320 @default.
• W3016810014 hasConcept C71924100 @default.
• W3016810014 hasConcept C84393581 @default.
• W3016810014 hasConceptScore W3016810014C126322002 @default.
• W3016810014 hasConceptScore W3016810014C134018914 @default.
• W3016810014 hasConceptScore W3016810014C159641895 @default.
• W3016810014 hasConceptScore W3016810014C2777180221 @default.
• W3016810014 hasConceptScore W3016810014C2778384471 @default.
• W3016810014 hasConceptScore W3016810014C2779284873 @default.
• W3016810014 hasConceptScore W3016810014C2779306644 @default.
• W3016810014 hasConceptScore W3016810014C2780323712 @default.
• W3016810014 hasConceptScore W3016810014C2780533449 @default.
• W3016810014 hasConceptScore W3016810014C555293320 @default.
• W3016810014 hasConceptScore W3016810014C71924100 @default.
• W3016810014 hasConceptScore W3016810014C84393581 @default.
• W3016810014 hasIssue "7" @default.
• W3016810014 hasLocation W30168100141 @default.
• W3016810014 hasLocation W30168100142 @default.
• W3016810014 hasLocation W30168100143 @default.
• W3016810014 hasLocation W30168100144 @default.
• W3016810014 hasOpenAccess W3016810014 @default.
• W3016810014 hasPrimaryLocation W30168100141 @default.
• W3016810014 hasRelatedWork W1518543897 @default.
• W3016810014 hasRelatedWork W1980852401 @default.
• W3016810014 hasRelatedWork W2107949845 @default.
• W3016810014 hasRelatedWork W2131505599 @default.
• W3016810014 hasRelatedWork W2214040177 @default.
• W3016810014 hasRelatedWork W2460294411 @default.
• W3016810014 hasRelatedWork W2624999659 @default.
• W3016810014 hasRelatedWork W2979734103 @default.
• W3016810014 hasRelatedWork W4241703347 @default.
• W3016810014 hasRelatedWork W4283159662 @default.

• next